CSS
AKRO

Cubist Systematic Strategies’s Akero Therapeutics AKRO Stock Holding History

Cubist Systematic Strategies’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-174,960
Closed -$7.08M – 2920
2025
Q1 		$7.08M Buy
174,960
+144,752
+479% +$6.14M 0.04% 680
2024
Q4 		$840K Buy
+30,208
New +$915K 0.01% 1900
2024
Q2 		– Sell
-7,119
Closed -$180K – 2905
2024
Q1 		$180K Buy
7,119
+1,883
+36% +$45.2K ﹤0.01% 3117
2023
Q4 		$122K Sell
5,236
-19,010
-78% -$375K ﹤0.01% 3134
2023
Q3 		$1.23M Buy
+24,246
New +$1.13M 0.01% 1732
2023
Q2 		– Sell
-19,778
Closed -$757K – 3432
2023
Q1 		$757K Sell
19,778
-95,706
-83% -$4.27M ﹤0.01% 2405
2022
Q4 		$6.33M Sell
115,484
-1,691
-1% -$72.5K 0.04% 816
2022
Q3 		$3.99M Buy
117,175
+96,932
+479% +$1.48M 0.02% 1300
2022
Q2 		$191K Buy
20,243
+12,277
+154% +$128K ﹤0.01% 3728
2022
Q1 		$113K Buy
7,966
+6,219
+356% +$109K ﹤0.01% 3208
2021
Q4 		$37K Sell
1,747
-1,211
-41% -$26.9K ﹤0.01% 3339
2021
Q3 		$66K Sell
2,958
-6,655
-69% -$151K ﹤0.01% 2804
2021
Q2 		$238K Buy
+9,613
New +$270K ﹤0.01% 2455
2021
Q1 		– Sell
-6,829
Closed -$176K – 2812
2020
Q4 		$176K Buy
6,829
+4,829
+241% +$134K ﹤0.01% 2284
2020
Q3 		$62K Buy
2,000
+1,280
+178% +$44.7K ﹤0.01% 2348
2020
Q2 		$18K Sell
720
-987
-58% -$22.6K ﹤0.01% 2319
2020
Q1 		$36K Buy
1,707
+658
+63% +$14.1K ﹤0.01% 2033
2019
Q4 		$23K Sell
1,049
-1,554
-60% -$32.2K ﹤0.01% 2335
2019
Q3 		$59K Sell
2,603
-1,957
-43% -$45.5K ﹤0.01% 2016
2019
Q2 		$87K Buy
+4,560
New +$86.4K ﹤0.01% 2254

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's AKRO Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 174,960 shares — an estimated $7.08M sold.

Cubist Systematic Strategies first reported a position in AKRO in Q2 2019 and held it in 20 quarters. The position peaked at $7.08M in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 174,960 Akero Therapeutics shares in Q2 2025, an estimated $7.08M.
  • Cubist Systematic Strategies first reported a position in Akero Therapeutics in Q2 2019 and held it in 20 quarters.
  • Cubist Systematic Strategies's Akero Therapeutics position peaked at $7.08M in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.